US Stock Insider Trading | Grail discloses nine insider transactions on March 9

K-LinePoet · 2026-03-17T19:20:36+00:00

Grail disclosed multiple insider transactions on March 9, 2026, with directors and executives selling over 10,000 shares collectively, involving amounts exceeding $1.3 million. The company focuses on developing early cancer detection technology, committed to improving health through innovation.

K-LinePoet

2026-03-17 19:20:36

Abstract generation in progress

On March 9, 2026, Grail (GRAL) disclosed nine insider trading transactions. Director RAGUSA ROBERT P sold 7,203 shares on March 9, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
March 9, 2026	Executive	Freidin Aaron	March 9, 2026	Sell	2,407	47.93	$115,400
March 9, 2026	Executive	Ofman Joshua J.	March 9, 2026	Sell	2,836	47.93	$135,900
March 5, 2026	Director	RAGUSA ROBERT P	March 5, 2026	Sell	980	53.01	$51,900
March 9, 2026	Executive	Freidin Aaron	March 9, 2026	Sell	85	46.74	$3,973
March 5, 2026	Executive	Freidin Aaron	March 5, 2026	Sell	655	53.01	$34,700
March 9, 2026	Executive	Ofman Joshua J.	March 9, 2026	Sell	101	46.74	$4,720
March 9, 2026	Director	RAGUSA ROBERT P	March 9, 2026	Sell	258	46.73	$12,100
March 9, 2026	Director	RAGUSA ROBERT P	March 9, 2026	Sell	7,203	47.93	$345,200
March 9, 2026	Executive	Ofman Joshua J.	March 5, 2026	Sell	690	53.01	$36,600
March 2, 2026	Executive	Ofman Joshua J.	March 2, 2026	Sell	16,200	50.09	$812,500

[Company Profile]

Grail, Inc. was incorporated in Delaware on September 11, 2015. The company is a healthcare organization dedicated to saving lives and improving health through pioneering new technologies for early cancer detection. It has assembled a multidisciplinary team of scientists, engineers, and physicians, leveraging next-generation sequencing (NGS), large-scale clinical studies, and cutting-edge computer and data science to tackle one of medicine’s biggest challenges. Using its platform technology, the company has developed a multi-cancer early detection blood test that has demonstrated in clinical studies the ability to detect over 50 types of cancer from a single blood draw with high accuracy in locating cancer signals.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.